Trexquant Investment LP Boosts Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Trexquant Investment LP boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 101.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 966,049 shares of the biopharmaceutical company’s stock after acquiring an additional 486,827 shares during the quarter. Trexquant Investment LP owned about 0.32% of Amicus Therapeutics worth $9,100,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of FOLD. Xponance Inc. increased its holdings in shares of Amicus Therapeutics by 11.9% in the 4th quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 2,249 shares in the last quarter. KBC Group NV grew its position in Amicus Therapeutics by 44.4% during the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock worth $96,000 after buying an additional 3,120 shares during the period. Swiss National Bank increased its holdings in Amicus Therapeutics by 0.7% in the fourth quarter. Swiss National Bank now owns 437,500 shares of the biopharmaceutical company’s stock valued at $4,121,000 after buying an additional 3,200 shares in the last quarter. Legacy Capital Group California Inc. lifted its position in shares of Amicus Therapeutics by 20.2% during the 4th quarter. Legacy Capital Group California Inc. now owns 23,229 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 3,900 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Amicus Therapeutics during the 3rd quarter worth approximately $55,000.

Amicus Therapeutics Stock Performance

Shares of NASDAQ FOLD opened at $7.99 on Thursday. The company has a 50-day simple moving average of $9.19 and a 200-day simple moving average of $9.90. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The company has a market cap of $2.45 billion, a PE ratio of -44.39, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. Amicus Therapeutics, Inc. has a 12 month low of $7.85 and a 12 month high of $12.65.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company dropped their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $16.75.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.